Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
        • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
      • Recently Published Guidelines
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
      • Brigham and Women's Hospital
      • Hartford Hospital
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Instituto do Coração-INCOR (São Paulo, Brasil)
      • Minneapolis City Hospital
      • Parkland Hospital: Dallas, Texas
      • Pennsylvania Hospital, Philadelphia
      • Pitié-Salpêtrière Hospital
      • Royal Infirmary of Edinburgh, Scotland
      • Tufts Medical Center
      • University of Michigan
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
      • Women's College Hospital, Toronto, Canada
      • Henry Ford Hospital, Detroit, Michigan
      • Instituto Nacional de Cardiología Ignacio Chávez – INCICh México City, México
      • Kuang-Tien General Hospital (Taichug, Taiwan)
      • University Hospital “Policlinico Umberto I”
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Basic Science Reports

In Vivo Evidence for a Role of Toll-Like Receptor 4 in the Development of Intimal Lesions

Aryan Vink, Arjan H. Schoneveld, Jelger J. van der Meer, Ben J. van Middelaar, Joost P.G. Sluijter, Mirjam B. Smeets, Paul H.A. Quax, Sai Kiang Lim, Cornelius Borst, Gerard Pasterkamp, Dominique P.V. de Kleijn
Download PDF
https://doi.org/10.1161/01.CIR.0000032146.75113.EE
Circulation. 2002;106:1985-1990
Originally published September 16, 2002
Aryan Vink
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arjan H. Schoneveld
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jelger J. van der Meer
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben J. van Middelaar
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost P.G. Sluijter
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mirjam B. Smeets
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul H.A. Quax
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sai Kiang Lim
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelius Borst
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard Pasterkamp
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique P.V. de Kleijn
From the Experimental Cardiology Laboratory (A.V., A.J.H., J.J.v.d.M., B.J.v.M., J.P.G.S., M.B.S., C.B., G.P., D.P.V.d.K.), Heart Lung Center Utrecht, University Medical Center Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (A.V., A.H.S., B.J.v.M., J.P.G.S., M.B.S., G.P., D.P.V.d.K.), Utrecht, the Netherlands; Genome Institute of Singapore (S.K.L.), National University of Singapore, Singapore; and TNO-PG (P.H.A.Q.), Leiden, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Background— Inflammation plays an important role in atherogenesis. The toll-like receptor 4 (TLR4) is the receptor for bacterial lipopolysaccharides and also recognizes cellular fibronectin and heat shock protein 60, endogenous peptides that are produced in response to tissue injury. To explore a possible role for this receptor in arterial obstructive disease, we determined the expression of TLR4 in the atherosclerotic arterial wall, including adventitia, and studied the effect of adventitial TLR4 activation on neointima formation in a mouse model.

Methods and Results— Localization of TLR4 was studied in human atherosclerotic coronary arteries by immunohistochemistry and detected in plaque and adventitia. In the adventitia, not all TLR4-positive cells colocalized with macrophages. In primary human adventitial fibroblasts, expression of TLR4 was demonstrated by immunofluorescence, Western blot, and reverse transcriptase-polymerase chain reaction. Adding lipopolysaccharide to these fibroblasts induced activation of NF-κB and an increase of mRNAs of various cytokines. The effect of adventitial stimulation of TLR4 was studied in a mouse model. A peri-adventitial cuff was placed around the femoral artery. Application of lipopolysaccharide between cuff and artery augmented neointima formation induced by the cuff (intimal area±SEM, 9134±1714 versus 2353±1076 μm2, P<0.01). In TLR4-defective mice, application of cuff and lipopolysaccharide resulted in a smaller neointima than in wild-type mice (intimal area, 3859±904 μm2, P=0.02 versus wild type).

Conclusions— A functional TLR4 is expressed in human adventitial fibroblasts and macrophages. Adventitial TLR4 activation augmented neointima formation in a mouse model. These results provide evidence for a link between the immune receptor TLR4 and intimal lesion formation.

  • atherosclerosis
  • inflammation
  • adventitia
  • fibroblast
  • immune system

Received April 30, 2002; revision received July 12, 2002; accepted July 12, 2002.

Atherosclerosis is considered an inflammatory disease.1 The presence of inflammatory cells in the intimal layer can be observed in all stages of atherosclerosis.2 A number of factors in the serum and endothelium, such as a high concentration of lipoproteins and endothelial dysfunction, probably play an important role in the influx of bone marrow-derived cells from the lumen into the arterial wall.1 The influx of macrophages and T-lymphocytes in atherosclerosis is not limited to the luminal side of the arterial wall. Adventitial inflammation has been associated with clinically manifested atherosclerotic lesions.3 The composition of these adventitial inflammatory infiltrates suggests a local immune response,4 but the trigger for this immune reaction is unknown. Infections have been suggested as potential triggers of arterial inflammation, but results have been conflicting and no causal relationship has been demonstrated.

In the innate immune system, cells can be activated by pathogens via the recently characterized family of toll-like receptors.5,6⇓ The toll-like receptor 4 (TLR4) is specific for lipopolysaccharide (LPS), 7 which is a major component of the outer layer of Gram-negative bacteria. In addition, cellular fibronectin, which is produced in response to tissue injury, and heat shock protein 60 (HSP60), which can be either autologous or from microorganisms, have also been described as activators of TLR4.8,9⇓ The expression of TLR4 has recently been described in macrophages and endothelial cells in the atherosclerotic plaque.10,11⇓ However, in vivo evidence for involvement of this receptor in the development of intimal lesions has not yet been provided.

We studied the location of cells expressing TLR4 in the human atherosclerotic arterial wall and observed expression in parts of the plaque but also in a large number of cells in the adventitia. In the adventitia, fibroblasts are the most prominent cells and the involvement of adventitial fibroblasts in the formation of intimal lesions has been demonstrated in animal models.12,13⇓ We report that next to macrophages, human adventitial fibroblasts express a functional TLR4. Activation of TLR4 in adventitial fibroblasts induced activation of NF-κB and the production of cytokines, suggesting that this cell type has TLR4-dependent immunoregulatory functions. To determine the role of TLR4 in the development of intimal lesions, we used a mouse femoral cuff model. Adventitial stimulation of TLR4 augmented neointima formation, an effect that was reduced in TLR4-defective mice. This result provides evidence for a link between the immune receptor TLR4 and intimal lesion formation.

Methods

Immunohistochemistry

Human coronary artery segments (n=5) were obtained post mortem. Frozen sections were fixed in acetone containing 0.15% H2O2 and blocked with 10% normal goat serum. Sections were incubated with rabbit antihuman TLR4 immune serum (141:1500) and biotinylated goat antirabbit IgG (Vector Laboratories, Burlingame, Calif) containing 1% normal human serum, followed by streptavidin-horseradish peroxidase incubation and treatment with sodium acetate buffer containing 3-amino-9-ethyl carbazole. As negative control, the serum was replaced with PBS. For double staining of macrophages and TLR4, macrophages were visualized by detecting acid phosphatase, as described previously,15 and TLR4 was visualized with alkaline phosphatase (blue).

Mouse femoral artery paraffin sections were blocked with 10% normal horse serum and incubated with mouse α-actin (10 μg/mL, Sigma) for 1 hour at room temperature. Next, sections were incubated with biotin-labeled horse antimouse (Vector Laboratories, Burlingame, Calif) and visualized as above.

Primary Human Adventitial Fibroblasts

A small part of the thoracic aorta was dissected from human donor and recipient hearts (n=5) during heart transplantation. The adventitial layer was dissected (stripped) from the aorta and cells were isolated with the use of collagenase. The cells that attached in the first 6 hours were cultured in DMEM (Invitrogen), supplemented with L-glutamine, penicillin 100 U/mL, streptomycin 100 μg/mL, and 10% fetal bovine serum (Invitrogen), and used throughout passages 2 to 4. Extraction of RNA and protein was performed with the use of Tripure Isolation Reagent (Roche). Cells were activated with 100 ng/mL LPS (Escherichia coli serotype 055.B6, Sigma).

Immunocytochemistry

For double-immunofluorescence staining of TLR4 and vimentin in human primary fibroblasts, cells were fixed with formaldehyde and subsequently treated with 1% Triton ×100 in PBS, followed by incubation with rabbit antihuman TLR4 immune serum (1:1500), incubation with mouse antivimentin monoclonal antibody (Sigma-Aldrich, St Louis, Missouri), incubation with Texas red horse antimouse antibody (Vector) in combination with biotinylated goat antirabbit antibody, and, finally, incubation with streptavidin fluorescein (Vector).

Western Blotting

Denatured protein samples (8 μg/lane) were separated on an 8% SDS polyacrylamide gel and blotted to a Hybond-C membrane (Amersham Pharmacia). Incubation steps were done in 5% defatted dry milk in PBS/0.1% Tween 20. Blots were incubated with rabbit antihuman TLR4 immune serum, biotinylated goat antirabbit antibody, and streptavidin-horseradish peroxidase, respectively, and visualized with the use of the chemiluminescence technique.

Reverse Transcriptase-Polymerase Chain Reaction

Isolated RNA (n=5) was treated with DNAse and subsequently tested for the presence of genomic DNA by polymerase chain reaction without reverse transcription. Total RNA was converted to cDNA by use of the Ready to Go You Prime First system (Amersham). A primer set specific for TLR4 (5′-TCAGCTC-TGCCTTCACTAC-3′ and 5′ -ACACCACAACAATCACCTTTC-3′) was used for amplification during 30 cycles at 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for 30 seconds. The identity of the amplified TLR4 cDNA was confirmed by sequence analysis.

RNAse Protection Assay

RNA (2 μg) was used in an RNAse protection assay (Pharmingen). Radioactive RNA probes were generated with the use of templates HCK-2 and HCK-5 and T7 RNA polymerase (Roche). Protected fragments were quantified and compared with the housekeeping gene GAPDH after film development by use of Gel Doc 1000 system (BioRad).

Electrophoretic Mobility Shift Assay

To isolate nuclei, cells were lysed in buffer containing 10 mmol/L HEPES-KOH (pH 7.9), 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.1% Nonidet P-40, 0.2 mmol/L PMSF, and 0.5 mmol/L DTT. After centrifuging, protein was isolated by suspending the nuclei in buffer containing 20 mmol/L HEPES-KOH, 1.5 mmol/L MgCl2, 420 mmol/L NaCl, 0.2 mmol/L EDTA, 25% glycerol, 0.5 mmol/L DTT, and 0.2 mmol/L PMSF on ice and centrifuged. Binding reactions were performed with 10 μg nuclear protein and 0.1 pmol 32P-labeled oligodeoxynucleotide in buffer containing 4% glycerol, 1 mmol/L MgCl2, 0.5 mmol/L EDTA, 0.5 mmol/L DTT, 50 mmol/L NaCl, 10 mmol/L Tris-HCl pH 7.5, 0.05 mg/mL poly(dI-dC) (Amersham) in the absence or presence of anti-p65 NF-κB antibody (Santa Cruz Biotechnologies, Santa Cruz, Calif). DNA complexes were separated on a 4% polyacrylamide gel. The oligodeoxynucleotides contained the NF-κB or AP-1 binding site (Promega, Leiden, Netherlands).

Animal Experiments

The local ethics committee on animal experiments approved all animal experiments. Female wild-type BALB/c and C.C3H-Tlr4lps-d mice (Jackson Laboratory, Bar Harbor, Me), aged 12 to 20 weeks, were anesthetized with the use of 0.025 mL/10 g body weight of a cocktail (ketaminehydrochloride 115, 3 mg/mL, xylazine 10 mg/mL, atropine 0.5 mg/mL, NaCl 0.9% in the ratio 7:6:2:7, respectively). A nonconstrictive polyethylene cuff (0.40-mm inner diameter, 0.80-mm outer diameter, length 2.0 mm; Portex) was placed loosely around the right femoral artery.16,17⇓ Between the artery and the cuff, 2% gelatin with or without LPS (1 μg/μL) was injected (BALB/c mice with LPS, n=9; BALB/c mice without LPS, n=9; C.C3H-Tlr4lps-d mice with LPS, n=8). At 3 weeks, mice were perfused with PBS containing 0.1-mg/mL nitroglycerin and subsequently with 4% formaldehyde. Paraffin sections of the right femoral artery were stained with elastin-Van Gieson and hematoxylin-eosin. Three equally spaced cross sections were used in each mouse. With the use of computerized morphometric analysis, the intimal cross-sectional area between the lumen and the internal elastic lamina and the medial area between the internal and external elastic lamina were measured. The Mann-Whitney test was used to compare groups. Values are presented as mean± SEM.

Results

TLR4 Is Expressed in Adventitial Cells

We determined the expression of TLR4 in the arterial wall of human atherosclerotic coronary arteries with immunohistochemistry. We observed immunostaining in areas in the atherosclerotic plaque and in a large number of cells in the adventitia (Figure 1a). We then studied which adventitial cells express TLR4. Expression of TLR4 has predominantly been described in inflammatory cells. Because it is known that the adventitia of human atherosclerotic arteries contains macrophages, we performed a double staining for TLR4 and macrophages. In both adventitia and plaque we observed colocalization (Figure 1b). Not all cells with TLR4 immunostaining double-stained for macrophages (acid phosphatase), suggesting that other adventitial cells also express TLR4 (Figure 1b).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. TLR4 expression in cells in adventitia of human atherosclerotic coronary artery. a, Representative immunohistochemical staining of TLR4 (red) in human atherosclerotic coronary artery. A indicates adventitia; M, media; and arrow, one of the stained cells in adventitia. Bar is 35 μm. b, Double staining of TLR4 (blue) and macrophages (red). Bar is 15 μm. Open arrow indicates double-stained cell (macrophage expressing TLR4); arrow, single-stained cell (other cell type expressing TLR4).

TLR4 Is Expressed in Adventitial Fibroblasts

Fibroblasts are abundantly present in the adventitia. We hypothesized that next to the adventitial macrophage, the adventitial fibroblast also expresses TLR4. To determine whether TLR4 is expressed in adventitial fibroblasts, we isolated primary adventitial fibroblasts from the adventitia stripped of human aortas. Double-immunofluorescence staining for TLR4 and vimentin demonstrated the expression of TLR4 in these vimentin-positive cells (Figure 2, a and b). Expression of TLR4 was confirmed by Western blot (Figure 2c) and reverse transcriptase-polymerase chain reaction (data not shown).

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Expression of TLR4 in human adventitial fibroblasts. Representative double-immunofluorescence staining of primary human adventitial fibroblasts stained for TLR4 (a) and vimentin (b). c, TLR4 detection by Western blot.

Increased NF-κB Activity Via TLR4

Activation of TLR4 induces activation of the transcription factor NF-κB.5,7⇓ To examine the effect of TLR4 activation on NF-κB activity in adventitial fibroblasts, we added LPS to primary cultures of human adventitial fibroblasts for 1 hour. Nuclear extracts of these cells were subjected to electrophoretic mobility shift assay (EMSA) and showed a shift specific for NF-κB (Figure 3). Thus, adding LPS to human adventitial fibroblasts resulted in activation of NF-κB.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. NF-κB activation in primary human adventitial fibroblasts after LPS stimulation. EMSA of isolated nuclear protein of nonstimulated (lane 2) and LPS stimulated (lanes 3 to 6) fibroblasts. Control EMSAs were performed without nuclear extract with NF-κB probe (lane 1), in the presence of 50 times excess cold NF-κB probe (lane 4), 50 times excess cold irrelevant AP1 probe (lane 5), and an antibody directed against the p65 subunit of NF-κB (lane 6). Representative results of 2 separate experiments.

Induction of Cytokine Production Via TLR4

Signaling via TLR4 leads to the activation of NF-κB, which induces the transcription of proinflammatory genes.18 We studied whether activation of primary human adventitial fibroblasts via TLR4 resulted in an increase of mRNA levels of various cytokines. Therefore, we cultured primary human adventitial fibroblasts in the presence of LPS for 0, 6, 12, and 24 hours. With the use of an RNAse protection assay we measured the mRNA levels of different cytokines. We observed an upregulation on mRNA level of the following cytokines: IL-1α (24× increased), IL-1β (42×), IL-1Ra (20×), IL-6 (14×), IFN-γ (16×), RANTES (110×), interferon-inducible protein-10 (IP-10, 130×), macrophage inflammatory protein (MIP-1β, >50×), monocyte chemotactic protein-1 (MCP-1, 100×), and IL-8 (50×) (Figure 4). For all cytokines, the highest mRNA level was observed at 6 or 12 hours. IL-12p35, IL-12p40, Ltn, MIP-1α, and I-309 were not detected.

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. Upregulation of various cytokines after stimulation of primary human adventitial fibroblasts with LPS for 0, 6, 12, and 24 hours. Representative results of 3 RNAse protection assays.

Adventitial TLR4 Activation in Wild-Type and TLR4-Defective Mice

Having demonstrated that adventitial cells express TLR4 and produce proinflammatory cytokines after LPS stimulation, we hypothesized that activation of TLR4 via the adventitial application of LPS results in migration of cells to the intima to form a neointima. To test this hypothesis, we studied the effect of periadventitial TLR4 activation on neointima formation by placing a nonconstrictive cuff around the femoral artery of BALB/c mice and injecting gelatin with or without LPS between the cuff and the artery. After 3 weeks’ follow-up, the group with adventitial LPS application showed a larger intimal area compared with the group without LPS (intimal areas 9134±1714 and 2353±1076 μm2, respectively, P<0.01, Figure 5). Thus, adventitial LPS application augmented neointima formation induced by a cuff. C.C3H-Tlr4lps-dmice are BALB/c mice that express a nonfunctional TLR4. To study whether the LPS-induced neointima formation was induced via TLR4, we performed the same operation in this mouse strain. In the C.C3H-Tlr4lps-d mice, cuff placement and LPS-gelatin application resulted in a smaller neointima formation (3859±904 μm2) compared with the wild-type BALB/c mice treated with cuff and LPS-gelatin (P=0.02, Figure 5).

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 5. Stimulation of TLR4 by adventitial application of LPS-augmented neointima formation in mouse model. Elastin-van Gieson staining of cross section of femoral artery of wild-type BALB/c mouse treated with periadventitial cuff and gelatin (a), with cuff and gelatin containing LPS (b), and TLR4-defective BALB/c mouse treated with cuff and LPS-gelatin (c). Sections are representative for the intimal area. d, Mouse α-actin staining. Bar is 30 μm. Intima/media ratio (e) and intimal area (f) of wild-type (Wt) BALB/c and TLR4-defective BALB/c mice treated with periadventitial cuff and gelatin (open bars) or LPS-gelatin (solid bars). *P< 0.05.

Discussion

Inflammatory and immune reactions probably play an important role in the development of atherosclerosis.1 The inflammatory reaction in the atherosclerotic arterial wall is not limited to the luminal side of the vessel wall. Inflammatory infiltrates are frequently present in the adventitia of atherosclerotic arteries,3 and the abundant expression of human histocompatibility leukocyte antigen-DM in the adventitia suggests an active adventitial inflammatory process.19 Infectious organisms and autologous structures, such as HSP60, have been suggested as triggers of an arterial inflammatory reaction.20 Recently, the TLR4 has been suggested as a link between infection/inflammation and atherosclerosis.10 Thus far, 3 structures have been described as activators of TLR4. First, TLR4 recognizes LPS, a part of the outer membrane of Gram-negative bacteria.7 Recent studies demonstrated that particles of the Gram-negative bacterium Chlamydia pneumoniae are frequently present in the adventitia of atherosclerotic arteries.21,22⇓ Second, HSP60 has been described to activate the TLR4.9 Atherosclerosis has been associated with HSP60, which could be autologous or originate from microbial organisms.20,23⇓ Third, TLR4 recognizes an alternatively spliced fragment of cellular fibronectin, which is produced in response to tissue injury.8 In vivo experiments demonstrated that this fragment was present in the adventitia of injured arteries.24 The TLR4 might, therefore, serve as a receptor by which both bacterial particles and arterial injury can induce an inflammatory reaction.

Two recent studies described expression of TLR4 in cells of the atherosclerotic plaque.10,11⇓ These studies, however, were descriptive and focused on the atherosclerotic plaque, whereas the adventitia remained unexplored. The principal findings of the present study are that adventitial cells, including adventitial fibroblasts, express a functional TLR4 in human atherosclerotic arteries, and that the activation of TLR4 by adventitial application of LPS leads to the augmentation of intimal hyperplasia, which is considered the “soil” of atherosclerosis.25

Having demonstrated that not all TLR4-positive cells in the adventitia are macrophages, we searched to find which other cell type expresses this receptor. Recent insights have led to the concept that fibroblasts are key sites of cytokine synthesis, which initiates a cascade of events leading to inflammation.26 We demonstrated that adventitial fibroblasts, as the only vimentin-positive cell present in the adventitia, can act as immunologic cells and that signaling through TLR4 on adventitial fibroblasts leads to the production of proinflammatory cytokines. LPS activated NF-κB in human primary adventitial fibroblasts. This result is in accordance with the observation that a constitutively active mutant of TLR4 can induce the activation of NF-κB5 and with the finding that LPS induces NF-κB activity in cells that were transiently transfected with human TLR4.7 Activation of NF-κB leads to the synthesis of a number of proinflammatory mediators.18 We show that LPS induces the synthesis of a range of cytokines in human adventitial fibroblasts. Particularly, the chemokines RANTES, IP-10, MIP-1β, MCP-1, and IL-8 were highly upregulated after LPS exposure. All these chemokines are chemoattractants of monocytes and T cells and have been described in association with atherosclerotic disease.27 Proliferation and migration of smooth muscle cells (SMCs) are considered an important event in the development of atherosclerosis.1 A number of the cytokines that we observed to be upregulated in adventitial fibroblasts after TLR4 activation (IP-10, IL-1, IL-6, IL-8) influence smooth muscle proliferation and/or migration.28–30⇓⇓ In experiments with mice, cytokines like IL-1 and IL-6 have been directly associated with the development of atherosclerosis.31,32⇓ Because there are no specific markers to distinguish fibroblasts from SMCs and other undifferentiated cells, 13 the layer of origin from the cells in the intima remains unclear. Migration of SMCs can be stimulated via cytokines28–30⇓⇓ produced by adventitial fibroblasts, and the migration of fibroblasts can be stimulated after TLR4 activation with the use of LPS,33 suggesting that both cell types can contribute to intima formation after TLR4 activation.

We used a well-described mouse model of cuff placement around the adventitia of the femoral artery.16,17⇓ In this model, in which the induction of intima hyperplasia is minimally triggered by cuff placement alone, local activation of TLR4 by LPS in the adventitia induced an augmentation of the intima consisting of α -actin-positive cells. In the mouse strain with a defective TLR4, LPS gelatin application resulted in a smaller neointima than in the wild-type strain, which indicates that TLR4 was involved in neointima formation after adventitial LPS activation. A previous study34 showed that the implantation of an LPS-soaked cotton thread in the adventitia of the rat femoral artery induced intimal formation. We show that TLR4 is involved in this process and adventitial fibroblasts can act as immune-regulatory cells.

In summary, TLR4 is expressed in human adventitial fibroblasts and macrophages. Activation of TLR4 in human adventitial fibroblasts induces the production of proinflammatory cytokines, suggesting that adventitial fibroblasts are able to act as immune-regulatory cells. Activation of TLR4 by LPS in the adventitia augmented neointima formation in a mouse model, and the use of TLR4-defective mice confirmed involvement of TLR4 in this process. These results for the first time link the immune receptor TLR4 to intimal lesion formation in an in vivo situation. The TLR4 might be considered a potential candidate in the search for new targets to intervene in the development of arterial obstructive diseases.

Acknowledgments

This study was supported by the Netherlands Organization for Scientific Research (grants 902-16-222 and 906-26-213) and the Dutch Heart Foundation (grants 99-209 and 2001-162). We thank Dr R. Medzhitov (Yale University School of Medicine, New Haven, Conn) for providing the antihuman TLR4 immune serum, L.A. Kleij and R.E. Verloop for their technical help, and the heart transplantation team of our hospital for collaborating in obtaining the primary adventitial fibroblasts.

References

  1. ↵
    Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–26.
    OpenUrlCrossRefPubMed
  2. ↵
    Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association. Circulation. 1994; 89: 2462–2478.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Laine P, Kaartinen M, Penttila A, et al. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation. 1999; 99: 361–369.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Houtkamp MA, de Boer OJ, van der Loos CM, et al. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. J Pathol. 2001; 193: 263–269.
    OpenUrlCrossRefPubMed
  5. ↵
    Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997; 388: 394–397.
    OpenUrlCrossRefPubMed
  6. ↵
    Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A. 1998; 95: 588–593.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999; 274: 10689–10692.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001; 276: 10229–10233.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Ohashi K, Burkart V, Flohe S, et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000; 164: 558–561.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001; 104: 3103–3108.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Edfeldt K, Swedenborg J, Hansson GK, et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002; 105: 1158–1161.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Shi Y, O’Brien JE, Fard A, et al. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 1996; 94: 1655–164.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Li G, Chen SJ, Oparil S, et al. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation. 2000; 101: 1362–1365.
    OpenUrlAbstract/FREE Full Text
  14. Deleted in proof.
  15. ↵
    Gerritse K, Laman JD, Noelle RJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1996; 93: 2499–2504.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Moroi M, Zhang L, Yasuda T, et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998; 101: 1225–1232.
    OpenUrlCrossRefPubMed
  17. ↵
    Lardenoye JH, Delsing DJ, de Vries MR, et al. Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. Circ Res. 2000; 87: 248–253.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NFkappa B. Annu Rev Cell Biol. 1994; 10: 405–455.
    OpenUrlCrossRef
  19. ↵
    Ramshaw AL, Parums DV. Immunohistochemical characterization of inflammatory cells associated with advanced atherosclerosis. Histopathology. 1990; 17: 543–552.
    OpenUrlCrossRefPubMed
  20. ↵
    Xu Q, Schett G, Perschinka H, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation. 2000; 102: 14–20.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Vink A, Pasterkamp G, Poppen M, et al. The adventitia of atherosclerotic coronary arteries frequently contains Chlamydia pneumoniae. Atherosclerosis. 2001; 157: 117–122.
    OpenUrlCrossRefPubMed
  22. ↵
    Meijer A, van der Vliet JA, Roholl PJ, et al. Chlamydia pneumoniae in abdominal aortic aneurysms: abundance of membrane components in the absence of heat shock protein 60 and DNA. Arterioscler Thromb Vasc Biol. 1999; 19: 2680–2686.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Sasu S, LaVerda D, Qureshi N, et al. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res. 2001; 89: 244–250.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Bauters C, Marotte F, Hamon M, et al. Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries. Circulation. 1995; 92: 904–911.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Stary HC, Blankenhorn DH, Chandler AB, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association. Circulation. 1992; 85: 391–405.
    OpenUrlFREE Full Text
  26. ↵
    Smith RS, Smith TJ, Blieden TM, et al. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol. 1997; 151: 317–322.
    OpenUrlPubMed
  27. ↵
    Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis. 1999; 147: 213–225.
    OpenUrlCrossRefPubMed
  28. ↵
    Barillari G, Albonici L, Incerpi S, et al. Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function. Atherosclerosis. 2001; 154: 377–385.
    OpenUrlCrossRefPubMed
  29. ↵
    Klouche M, Bhakdi S, Hemmes M, et al. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol. 1999; 163: 4583–4589.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Yue TL, Wang X, Sung CP, et al. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res. 1994; 75: 1–7.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Rectenwald JE, Moldawer LL, Huber TS, et al. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation. 2000; 102: 1697–1702.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Huber SA, Sakkinen P, Conze D, et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999; 19: 2364–2367.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    De Kleijn DP, Smeets MB, Kemmeren PP, et al. Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring. FASEB J. 2002; 16: 1123–1125.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Prescott MF, McBride CK, Court M. Development of intimal lesions after leukocyte migration into the vascular wall. Am J Pathol. 1989; 135: 835–846.
    OpenUrlPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation
October 8, 2002, Volume 106, Issue 15
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    In Vivo Evidence for a Role of Toll-Like Receptor 4 in the Development of Intimal Lesions
    Aryan Vink, Arjan H. Schoneveld, Jelger J. van der Meer, Ben J. van Middelaar, Joost P.G. Sluijter, Mirjam B. Smeets, Paul H.A. Quax, Sai Kiang Lim, Cornelius Borst, Gerard Pasterkamp and Dominique P.V. de Kleijn
    Circulation. 2002;106:1985-1990, originally published September 16, 2002
    https://doi.org/10.1161/01.CIR.0000032146.75113.EE

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    In Vivo Evidence for a Role of Toll-Like Receptor 4 in the Development of Intimal Lesions
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    In Vivo Evidence for a Role of Toll-Like Receptor 4 in the Development of Intimal Lesions
    Aryan Vink, Arjan H. Schoneveld, Jelger J. van der Meer, Ben J. van Middelaar, Joost P.G. Sluijter, Mirjam B. Smeets, Paul H.A. Quax, Sai Kiang Lim, Cornelius Borst, Gerard Pasterkamp and Dominique P.V. de Kleijn
    Circulation. 2002;106:1985-1990, originally published September 16, 2002
    https://doi.org/10.1161/01.CIR.0000032146.75113.EE
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Smooth Muscle Proliferation and Differentiation
    • Vascular Biology
    • Mechanisms
  • Genetics
    • Genetically Altered and Transgenic Models

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured